177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

NCT01237457 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 177Lu-DOTATATE

Sponsor

Ebrahim S Delpassand

Collaborators

[object Object]